EGFR and colon adenocarcinoma: The survival differences adjusted by the clinical stage indicated that CHRM1–5 and EGFR expression levels were significantly (p < 0.05) higher in stage 3 and also significantly (p < 0.001) higher in stage 4 than the other stages in COAD patients.